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Artemio M. Jongco, MPH, MD, PhDa,b, Jonathan D. Gough, PhDc, Kyle Sarnataroa, David W.
Rosenthal, DO, PhDa,b, Joanne Moreau, MDb, Punita Ponda, MDb, and Vincent R. Bonagura,
MDa,b
aLaboratory of Host Defense, Center for Immunology and Inflammation, Feinstein Institute for
Medical Research, Manhasset, New York
bDivision of Allergy and Immunology, Hofstra North Shore-LIJ School of Medicine, Great Neck,
New York
cDepartment of Chemistry and Biochemistry, Long Island University, Brooklyn, New York
Pneumocystis jirovecii pneumonia is an opportunistic pulmonary infection usually
associated with T-cell defects. Clinical and murine studies demonstrate that B-cells and
Pneumocystis-specific antibodies also contribute to effective immune responses.1 Patients
with primary humoral immunodeficiencies, including X-linked agammaglobulinemia
(XLA), may develop P . jirovecii pneumonia despite normal T-cell number and function.2,3
XLA arises from Bruton tyrosine kinase (BTK) gene mutations, leading to pre-B-cell
differentiation arrest, absence of immunoglobulin expression, and increased susceptibility to
bacterial/enteroviral infections.4 Although more than 600 BTK mutations have been
described, new variations/mutations continue to be identified. We describe an infant with a
novel BTK kinase domain variation who presented with polymicrobial pneumonia,
including P. jirovecii.
A 4-month-old former pre-term male infant, born to non-consanguineous parents, without
family history of primary or secondary immunodeficiencies, was evaluated for
agammaglobulinemia and polymicrobial pneumonia. Newborn screening was unremarkable,
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including T-cell receptor excision circle level and HIV-1. He tolerated 2-month
vaccinations. He was admitted at age 3.5 months for intermittent increased work of
breathing and tachypnea. Chest x-ray (CXR) was normal. He was treated with nebulized
albuterol and prednisone. After a short prednisone course, he developed persistent tachypnea
and hypoxia, and was admitted to intensive care at age 4 months. On physical examination,
lymph node and tonsils were undetectable. Although CXR was normal, chest computed
tomography scan showed diffuse ground glass opacities in the right middle lobe.
Bronchoscopy was performed and bronchoalveolar lavage (BAL) was positive for
Pneumocystis jirovecii, Klebsiella pneumoniae and Pseudomonas aeruginosa. Serum IgG,
IgA, IgM, and IgE were undetectable. CBC, C3/C4 levels were normal. Blood and viral
cultures were negative. Immunologic evaluation revealed B-cell lymphopenia, elevated
CD4+CD45RO+ and decreased CD4+CD45RA+ T-cells (Table I).5 He responded well to
piperacillin/tazobactam, trimethoprim/sulfamethoxazole (TMP-SMX), methylprednisolone,
and intravenous immunoglobulin, 0.4 g/kg. He completed 3 weeks of treatment dose TMP-
SMX followed by prophylactic dosing. After 1 week, he presented with transient tachypnea.
CXR showed bilateral perihilar infiltrates. Silver stain, viral and BAL cultures were
negative. He responded to azithromycin and transitioned to subcutaneous immunoglobulin,
0.1 g/kg weekly. He remains well and infection-free with IgG trough levels >500 mg/dL.
BTK genomic sequencing and concurrent targeted array comparative genomic hybridization
analysis by GeneDx showed a single adenosine deletion in exon 17 within the kinase
domain, causing a frameshift and premature stop codon at residue 569 (c.1701delA
(p.Val568SerfsX2)). This variation has not been reported previously in BTKbase version
8.52 or Universal Protein Resource. Two prediction programs, PROVEAN6 v1.1.3 and
MutationTaster6, predicted significantly impaired protein function. MutationTaster7 reported
another distinct disease-causing mutation at this position. No BTK gene deletion or
duplication was identified. BTK expression in peripheral blood mononuclear cells (PBMCs)
was evaluated by western blot. Using an anti-amino-terminal antibody recognizing residues
11–26, the control expressed the 76 kiloDalton (kDa) wild type protein, the patient
expressed an approximately 66 kDa truncated mutant, while the mother expressed both wild
type and truncated proteins, consistent with a BTK carrier. The approximately 60 kDa band
detected in all samples likely represents non-specific binding (Supplemental figure 1A).
Using an anti-carboxyl-terminal antibody recognizing residues 642-659, the patient had
undetectable protein, while the mother expressed diminished wild type protein compared to
control (Supplemental figure 1A).
We hypothesized that this expressed truncated protein would be dysfunctional in all BTK-
expressing cells. The kinase domain is highly conserved among BTK homologs from
diverse organisms, such as zebrafish to primates (data not shown), suggesting that drastic
mutations are likely deleterious to proper function. BTK activation begins with
transphosphorylation of Y551 in the activation loop (residues 542-559) of the kinase domain
by Src-family kinase, followed by autophosphorylation of Y223 in the SH3 domain. X-ray
crystal structures of human BTK kinase domain show the importance of Y551 conformation
for optimal catalysis and activity.8 Molecular dynamics modeling revealed that the truncated
protein structurally differs from wild type starting from L547 within the activation loop.
Furthermore, Y551 conformationally differs from wild type BTK (Supplemental figure 1B).
Thus, the altered structure would impair optimal Y551 transphosphorylation and subsequent
Y223 autophosphorylation. Western blot of PBMCs using phosphorylated Y223-specific
antibody revealed the patient had undetectable phospho-Y223, whereas his mother
expressed reduced levels compared to control (Supplemental figure 1C). These findings
suggest that the mutant BTK is inactive.
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P. jirovecii pneumonia remains an atypical XLA presentation. Although Pneumocystis-
specific antibodies are detectable in humans and suspected to be protective based on murine
studies, their clinical significance is unclear.1 Prematurity or corticosteroid use may
contribute to increased P . jirovecii susceptibility in XLA patients who rarely develop
opportunistic infections.9 Since BTK is expressed in all hematopoietic cells except T- and
plasma cells, BTK deficiency may contribute to antigen presenting cell (APC) dysfunction,
leading to impaired innate/adaptive immunity in XLA patients.10 Recent data suggest that
BTK may be a negative regulator of TLR-induced inflammation.11 APC and T-cell function
are not universally impaired. XLA patients demonstrate normal APC and T-cell responses to
influenza virus12–13 and hepatitis B virus14 but appear unable to develop lasting T-cell
memory responses to meningococcus,12 suggesting heterogeneity in the ability of XLA
patients to respond and maintain T-cell responses to different pathogens. Another possibility
is that drastic changes, like kinase domain truncations, may cause more severe phenotypes,
but genotype-phenotype correlations are not well established in XLA. Although we did not
test APC activation/function in this patient, we suspect that the mutant BTK could cause
APC dysfunction. Delayed type hypersensitivity (DTH) to tetanus toxoid at 16 months of
age off any corticosteroids, was absent in this patient. Decreased DTH, associated with
reduced CD4+CD45RO+ memory T-cells, has been reported previously in XLA patients,15
but the underlying mechanism is unclear. This could reflect differences in: 1) local versus
circulating APCs; 2) pathogen route of entry/exposure and the efficacy of the ensuing
response; 3) severity of the underlying genotype; or 4) altered kinetics of T-cell response in
patients versus controls.12–15
B-cell lymphopenia may also perturb proper T-cell maturation/function. Reduced memory
T-cells have been reported in XLA patients and common variable immunodeficiency
(CVID) patients with <2% B-cells,16 suggesting that B-cell lymphopenia, not BTK
deficiency per se, may contribute to impaired CD4 + T-cell maturation. Murine studies
suggest that clearance of Pneumocystis depends on B-cell-mediated activation and
expansion of effector and memory T-cells.1,17 Current data are conflicting on whether B-
cells are dispensable in generating effective T-cell memory in humans.12–16 Elevated
CD4+CD45RO+ memory T-cells has been reported in CVID patients,18 but its significance
in our patient or his absent DTH is unclear. Further research is needed to investigate these
possibilities.
In summary, this patient is a reminder that P. jirovecii pneumonia should be considered in
XLA patients presenting with respiratory distress. Although BTK is not expressed in T-cells,
BTK deficiency may indirectly affect optimal T-cell maturation/activation by modulating
APC function. The potential consequences of BTK deficiency in cells other than B-cells
should be considered, especially since BTK inhibitors, which irreversibly block BTK
activation and function, are being developed for clinical use in malignancy and autoimmune
diseases.19
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Table I
Summary of clinical laboratory evaluation.
Test Result Age-appropriate reference range
CD3+ 3602 (91%) 2500–5600 cells/μL (51–77%)
CD4+ 2030 (51%) 1800–4000 cells/μL (35–56%)
CD8+ 1461 (37%) 590–1600 cells/μL (12–23%)
CD19+ 12 (<1%) 430–3000 cells/μL (11–14%)
CD16+CD56+ 325 (8%) 170–830 cells/μL (3–14%)
CD4+45RA−45RO+ 24% 3–16%*
CD4+45RA+45RO− 58% 77–94%*
CD8+45RA−45RO+ 2% 1–7%*
CD8+45RA+45RO− 95% 85–98%*
Lymphocyte proliferation PHA: Wnl
ConA: Wnl
PWM: Wnl
PHA: Wnl
ConA: Wnl
PWM: Wnl
Natural Killer Cell cytolysis Wnl Wnl
IgG Undetectable 251–906 mg/dL
IgA Undetectable 4–73 mg/dL
IgM Undetectable 27–101 mg/dL
IgE Undetectable 0.18–3.76 IU/mL
C3 97 62–175 mg/dL
C4 27 8.3–38 mg/dL
Sweat test Negative Negative
Tetanus toxoid DTH No wheal or flare Wheal and flare
ConA, concanavilin A; DTH, delayed type hypersensitivity; PHA, phytohemagglutinin; PWM, pokeweed mitogen; Wnl, within normal limits.
*
age appropriate reference ranges from reference 5.
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